natgillin/translations-raw huggingface dataset:
Der er rapporteret om antibiotika-relateret kolitis og pseudomembranøs kolitis ved anvendelse af næsten alle antibiotika, og disse bivirkninger kan være lette til livstruende. 
Antibiotic-associated colitis and pseudomembranous colitis have been reported with the use of nearly all antibiotics and may range in severity from mild to life-threatening.
Tabel 1 Oversigt over bivirkninger ved eravacyclin i kliniske studier 
Table 1 Tabulated list of adverse reactions to eravacycline in clinical trials
Doser, der var 2 eller 4 gange højere end kliniske eksponering (baseret på AUC), var forbundet med maternel toksicitet (kliniske observationer og reduceret vækst og fødeindtag), reduceret fostervægt og forsinket knogledannelse hos begge arter samt abort hos kaniner. 
Doses more than 2- or 4-fold higher than the clinical exposure (based on AUC) were associated with maternal toxicity (clinical observations and reduced body weight gain and food consumption), and reduced foetal body weights and delays in skeletal ossification in both species and abortion in the rabbit.
Pankreatitis Diarré 
Pancreatitis Diarrhoea
Xerava er derfor ikke indiceret til behandling af komplicerede urinvejsinfektioner. 
Xerava is therefore not indicated for the treatment of complicated urinary tract infections.
Anbefalet størrelse af infusionsposen 
Recommended infusion bag size
En lægemiddelinteraktion in vivo kan ikke udelukkes, og samtidig administration af eravacyclin og andre lægemidler, der hæmmer disse transportere, kan øge plasmakoncentrationen af eravacyclin (eksempler på OATP1B1/3-hæmmere: atazanavir, cyclosporin, lopinavir og saquinavir). 
A drug-drug interaction in vivo cannot be excluded and co-administration of eravacycline and other medicinal products that inhibit these transporters (examples of OATP1B1/3 inhibitors; atazanavir, cyclosporine, lopinavir, and saquinavir) may increase the eravacycline plasma concentration.
mannitol (E421), natriumhydroxid, saltsyre 
mannitol (E421), sodium hydroxide, hydrochloric acid
Samtidig administration af den potente CYP3A4/3A5-inducer rifampicin ændrede eravacyclins farmakokinetik ved at reducere eksponeringen med ca. 32 % og øge clearance med ca. 54 %. 
Concomitant administration of the strong CYP 3A4/3A5 inducer rifampicin altered the pharmacokinetics of eravacycline, decreasing exposure by approximately 32% and increasing clearance by approximately 54%.
Din læge kan øge dosen (1,5 mg/kg hver 12. time), hvis du tager andre lægemidler som f.eks. rifampicin, phenobarbital, karbamazepin, phenytoin eller prikbladet perikon. 
Your doctor may increase your dose (1.5 mg/kg every 12 hours) if you are taking other medicines including rifampicin, phenobarbital, carbamazepine, phenytoin, or St. John's Wort.
Som for andre antibiotika i tetracyclin-klassen kan eravacyclin forårsage permanente tanddefekter (misfarvning og emaljedefekter) og forsinkede ossifikationsprocesser hos fostre, der eksponeres in utero i 2. og 3. trimester, på grund af akkumulering i væv med høj kalciumomsætning og dannelse af kalciumkelat-komplekser (se pkt. 
As for other tetracycline class antibiotics, eravacycline may induce permanent dental defects (discolouration and enamel defects) and a delay in ossification processes in foetuses exposed in utero during the 2nd and 3rd trimester, due to accumulation in tissues with a high calcium turnover and formation of calcium chelate complexes (see sections 4.4 and 5.3).
I embryoføtale studier sås ingen bivirkninger hos rotter ved eksponeringer svarende til den kliniske eksponering eller hos kaniner ved eksponeringer, der var 1,9 gange større end den kliniske eksponering (baseret på AUC). 
In embryo-foetal studies, no adverse effects were observed in rats at exposures comparable to clinical exposure or in rabbits at exposures 1.9-fold higher than the clinical exposure (based on AUC) in rats and rabbits respectively.
Klasseeffekter for tetracycliner omfatter lysfølsomhed, pseudotumor cerebri og anti-anabolisk indvirkning, der har ført til forhøjet karbamid, azotæmi, acidose og hyperfosfatæmi. 
Tetracycline class adverse reactions include photosensitivity, pseudotumor cerebri, and anti-anabolic action which have led to increased BUN, azotaemia, acidosis, and hyperphosphataemia.
• rødme eller hævelse på injektionsstedet. 
• Redness or swelling at the site of the injection
Opbevar hætteglasset i den indre karton for at beskytte mod lys. 
Keep the vial in the inner carton in order to protect from light.
Der er påvist kemisk og fysisk brugsstabilitet efter fortynding i infusionsposen i 72 timer ved opbevaring i køleskab (2-8 °C) . 
Chemical and physical in-use stability after dilution in the infusion bag has been demonstrated for 72 hours at refrigerated conditions (2-8°C) .
Bivirkninger, der er set ved eravacyclin, er vist i tabel 1. 
The adverse reactions identified with eravacycline are presented in Table 1.
Alvorlige og i nogle tilfælde fatale overfølsomhedsreaktioner kan opstå og er blevet indberettet ved anvendelse af andre antibiotika i tetracyclin-klassen (se pkt. 
Serious and occasionally fatal hypersensitivity reactions are possible and have been reported with other tetracycline class antibiotics (see section 4.3).
Eravacyclin er et substrat for transporterne P-gp, OATP1B1 og OATP1B3, men ikke for BCRP. 
Eravacycline is a substrate for the transporters P-gp, OATP1B1 and OATP1B3 but not for BCRP.
Du må ikke tage medicin mod diarré, før du har talt med lægen (se også pkt. 
Do not take any medicine to treat your diarrhoea without first checking with your doctor (see also section 4).
Hvad anvendes Xerava til? 
What Xerava is used for
Type I-hætteglas (10 ml) af glas med klorobutylgummiprop og aluminiumshætte. 
10mL Type I glass vial with chlorobutyl rubber stopper and aluminium cap.
- Øvrige indholdsstoffer: mannitol (E421), saltsyre (til justering af pH) og natriumhydroxid (til justering af pH). 
- The other ingredients are mannitol (E421), hydrochloric acid (for pH adjustment) and sodium hydroxide (for pH adjustment).
Samtidig administration af den potente CYP3A-hæmmer itraconazol ændrede eravacyclins farmakokinetik ved at øge Cmax med ca. 5 % og AUC0-24 med ca. 23 % samt reducere clearance. 
Concomitant administration of the strong CYP3A inhibitor itraconazole altered the pharmacokinetics of eravacycline, increasing Cmax by approximately 5% and AUC0-24 by approximately 23%, and decreasing clearance.
Intravenøs administration af høje doser eravacyclin har været forbundet med hudreaktioner (herunder nældefeber, kløe, hævelse og/eller erytem) i studier af rotter og hunde. 
Intravenous administration of high doses of eravacycline has been associated with cutaneous responses (including hives, scratching, swelling, and/or skin erythema) in rat and dog studies.
Kliniske studier har ikke påvist nogen effekt af Xerava til behandling af komplicerede urinvejsinfektioner. 
Clinical trials have failed to demonstrate the efficacy of Xerava for the treatment of complicated urinary tract infections.
Eravacyclin kan administreres uden hensyn til tidspunkterne for hæmodialyse (se pkt. 
Eravacycline may be administered without regard to the timing of haemodialysis (see section 5.2).
Patienter, der får potente CYP3A-hæmmere (f.eks. ritonavir, itraconazol eller clarithromycin) med en kombination af faktorer, der kan øge eksponeringen, herunder svært nedsat leverfunktion og/eller overvægt, bør imidlertid overvåges for bivirkninger (se pkt. 
However, patients receiving strong CYP3A inhibitors (for example ritonavir, itraconazole, clarithromycin) with a combination of factors that may increase the exposure, such as severe hepatic impairment and/or obesity should be monitored for adverse reactions (see sections 4.4 and 4.8).
I en farmakokinetisk populationsanalyse af eravacyclin sås ingen klinisk relevante forskelle mellem kønnene, hvad angår AUC. 
In a population pharmacokinetic analysis of eravacycline, no clinically relevant differences in AUC by gender were observed for eravacycline.
Tabel 3 Eksempler på beregninger for legemsvægt i intervallet 40-200 kg 
Table 3 Example calculations for weights ranging from 40 kg to 200 kg
Det er ukendt, om Xerava udskilles i human mælk. 
It is not known if Xerava passes into breast milk.
Symptomerne er udslæt, hævelse i ansigtet, ørhed eller svimmelhed, trykken for brystet, vejrtrækningsbesvær, hurtig hjerterytme eller bevidsthedstab (se også pkt. 
Symptoms to look out for include rash, swelling of the face, feeling lightheaded or faint, tightness of the chest, breathing difficulties, fast heartbeat, or losing consciousness (see also section 4).
Det er påvist in vitro, at eravacyclin er et substrat for transporterne P-gp, OATP1B1 og OATP1B3. 
In vitro, eravacycline was shown to be a substrate for the transporters P-gp, OATP1B1 and OATP1B3.
Andre tetracyclin-holdige antibiotika 
Other tetracycline antibiotics
Eravacyclin og dets metabolitter er ikke hæmmere af CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 og CYP3A4 in vitro. 
Eravacycline and its metabolites are not inhibitors of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A4 in vitro.
Fortæl det til lægen eller sundhedspersonalet, hvis du får diarré under eller efter behandlingen. 
Tell your doctor or nurse straightaway if you develop diarrhoea during or after your treatment.
Xerava fås i pakninger med 1 hætteglas eller multipakninger bestående af 12 kartoner med hver 1 hætteglas. 
Xerava is available in packs containing 1 vial or multipacks comprising 12 cartons, each containing 1 vial.
Xerava anvendes til at behandle voksne med en kompliceret maveinfektion. 
Xerava is used to treat adults with a complicated infection in the abdomen.
• betændelse i en blodåre, der forårsager smerter og hævelse (flebitis) 
• Inflammation of a vein causing pain and swelling (phlebitis)
De hyppigste bivirkninger i kliniske studier af patienter med komplicerede intraabdominale infektioner i behandling med eravacyclin (n = 576) var kvalme (3,0 %), opkastning, flebitis ved infusionsstedet (begge 1,9 %), flebitis (1,4 %), trombose ved infusionsstedet (0,9 %), diarré (0,7 %), erytem ved indstiksstedet (0,5 %), hyperhidrose, tromboflebitis, hypoæstesi ved infusionsstedet og hovedpine (hver 0,3 %), og de var typisk af let til moderat sværhedsgrad. 
In clinical trials, the most common adverse reactions in patients with cIAI treated with eravacycline (n=576) were nausea (3.0%), vomiting, infusion site phlebitis (each 1.9%), phlebitis (1.4%), infusion site thrombosis (0.9%), diarrhoea (0.7%), vessel puncture site erythema (0.5%), hyperhidrosis, thrombophlebitis, infusion site hypoaesthesia, and headache (each 0.3%), which were generally mild or moderate in severity.
Pakningsstørrelser: 1 hætteglas og multipakninger med 12 (12 pakker á 1) hætteglas. 
Pack sizes: 1 vial and multipacks containing 12 (12 packs of 1) vials.
Det skal besluttes, om amning eller behandling med Xerava skal ophøre, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen. 
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Xerava should be made, taking into account the benefit of breast-feeding for the child, and the benefit of therapy for the woman.
MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE YDRE KARTON: MULTIPAKNING, INDEHOLDER BLUE BOX 
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON: MULTIPACK, CONTAINS BLUE BOX
Den klargjorte opløsning skal kontrolleres for synlige partikler inden administration. 
The ready to use solution should be inspected visually for particulate matter prior to administration.
Efter yderligere fortynding indeholder 1 ml opløsning 0,3 mg eravacyclin. 
After further dilution 1 mL contains 0.3 mg eravacycline.
Opbevar hætteglasset i kartonen for at beskytte mod lys. 
Keep the vial in the carton in order to protect from light.
Tabel 1 Eksempler på beregninger for legemsvægt i intervallet 40-200 kg 
Table 1 Example calculations for weights ranging from 40 kg to 200 kg
Samtidig administration af en potent CYP3A4-inducer (f.eks. phenobarbital, rifampicin, karbamazepin, phenytoin eller prikbladet perikon) forventes at reducere effekten af eravacyclin (se pkt. 
Co-administration of a strong CYP3A4 inducer (such as phenobarbital, rifampicin, carbamazepine, phenytoin, St. John's Wort) is expected to reduce the effect of eravacycline (see sections 4.2 and 4.5).
Der er rapporteret om lette til moderate reaktioner på infusionsstedet, herunder smerter eller ubehag, erytem og hævelse eller inflammation ved injektionsstedet samt overfladisk tromboflebitis og/eller flebitis hos patienter i behandling med eravacyclin. 
Mild to moderate infusion site reactions, including pain or discomfort, erythema and swelling or inflammation at the injection site as well as superficial thrombophlebitis and/or phlebitis have been reported in patients treated with eravacycline.
Hos patienter, der samtidig får potente CYP3A4-inducere, er det anbefalede dosisregime 1,5 mg/kg eravacyclin hver 12. time i 4-14 dage (se pkt. 
In patients co-administered strong CYP3A4 inducers the recommended dose regimen is 1.5 mg/kg eravacycline every 12 hours for 4 to 14 days (see sections 4.4 and 4.5).
Andre lægemidler, der kan påvirke eravacyclins farmakokinetik 
Potential for other medicinal products to affect the pharmacokinetics of eravacycline
Det geometriske AUC0-inf-gennemsnit for eravacyclin steg med hhv. 22,9 %, 37,9 % og 110,3 % hos patienter med let, moderat og svært nedsat leverfunktion vs. raske forsøgspersoner. 
The geometric mean AUC0-inf for eravacycline was increased by 22.9%, 37.9%, and 110.3% for subjects with mild, moderate, and severe hepatic impairment versus healthy subjects, respectively.
Hvert hætteglas bør rekonstitueres med 5 ml vand til injektionsvæsker og omrystes forsigtigt, indtil pulveret er helt opløst. 
Each vial should be reconstituted with 5 mL water for injections, and swirled gently until the powder has dissolved entirely.
• hævelse i ansigtet 
• Swelling of the face
Tromboflebitisa Flebitis b 
Thrombophlebitis a
Udslæt Hyperhidrose 
Rash Hyperhidrosis
Der sås misfarvning af knogler (ingen histologiske fund) hos rotter og aber efter 13 ugers dosering, en tilstand, der ikke var fuldt reversibel efter restitutionsperioder på op til 7 uger. 
Bone discolouration (in the absence of histological findings), which was not fully reversible over recovery periods of up to 7-weeks, was observed in rats and monkeys after 13 weeks of dosing.
I toksicitetsstudier med gentagne doser eravacyclin hos rotter, hunde og aber sås lymfoid depletion/atrofi i lymfeknuder, milt og brissel, nedsat antal erytrocytter, retikulocytter, leukocytter og trombocytter (hund og abe) i forbindelse med hypocellularitet i knoglemarven samt gastrointestinale bivirkninger (hund og abe). 
In repeated dose toxicity studies in rats, dogs and monkeys, lymphoid depletion/atrophy of lymph nodes, spleen and thymus, decreased erythrocytes, reticulocytes, leukocytes, and platelets (dog and monkey), in association with bone marrow hypocellularity, and adverse gastrointestinal effects (dog and monkey) were observed with eravacycline.
• bevidsthedstab. 
• Losing consciousness
Fortæl det til lægen eller sundhedspersonalet, hvis du tager anden medicin eller har gjort det for nylig (herunder rifampicin og clarithromycin (antibiotika), phenobarbital, karbamazepin og phenytoin (mod epilepsi), prikbladet perikon (naturlægemiddel mod depression og angst), itraconazol (mod svampeinfektioner), ritonavir, atazanavir, lopinavir og saquinavir (mod virusinfektioner) og cyclosporin (anvendes til at dæmpe immunforsvaret)). 
Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines including rifampicin and clarithromycin (antibiotics), phenobarbital, carbamazepine and phenytoin (used to treat epilepsy), St. John's Wort (a herbal remedy used for treatment of depression and anxiety) itraconazole (a medicine to treat fungal infections), ritonavir, atazanavir, lopinavir and saquinavir (medicines used to treat viral infections), and cyclosporine (a medicine used to suppress the immune system).
Søg straks lægehjælp, hvis du tror, at du oplever en anafylaktisk reaktion eller får et eller flere af følgende symptomer under behandlingen med Xerava: 
Seek urgent medical attention if you suspect you have an anaphylactic reaction, or develop any of the following symptoms, whilst receiving Xerava:
Det ønskede antal hætteglas skal hver især rekonstitueres med 5 ml vand til injektionsvæsker og drejes forsigtigt rundt, indtil pulveret er helt opløst. 
The contents of the required number of vials should each be reconstituted with 5 mL water for injections, and swirled gently until the powder has dissolved entirely.
Streptococcus spp. 
Viridans Streptococcus spp.
MÆRKNING, DER SKAL ANFØRES PÅ DEN INDRE EMBALLAGE INDRE KARTON: MULTIPAKNING, UDEN BLUE BOX 
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING INNER CARTON: MULTIPACK, CONTAINS NO BLUE BOX
Eravacyclin, TP-498 og TP-6208 er ikke inducere af CYP1A2, CYP2B6 og CYP3A4. 
Eravacycline, TP-498 and TP-6208 are not inducers of CYP1A2, CYP2B6 or CYP3A4.
Overfølsomhed over for antibiotika i tetracyclin-klassen. 
Hypersensitivity to tetracycline class antibiotics.
Det geometriske Cmax-gennemsnit for eravacyclin steg med hhv. 13,9 %, 16,3 % og 19,7 % hos patienter med let (Child-Pugh A), moderat (Child-Pugh B) og svært (Child-Pugh C) nedsat leverfunktion vs. raske forsøgspersoner. 
The geometric mean Cmax for eravacycline was increased by 13.9%, 16.3%, and 19.7% for subjects with mild (Child-Pugh Class A), moderate (Child-Pugh Class B), and severe (Child-Pugh Class C) hepatic impairment versus healthy subjects, respectively.
Xerava gives som infusionsvæske (drop) i en blodåre. 
Xerava is given by an infusion (drip) directly into your vein.
Der er påvist kemisk og fysisk brugsstabilitet efter fortynding i infusionsposen i 12 timer ved temperaturer på 25 °C. 
Chemical and physical in-use stability after dilution in the infusion bag has been demonstrated for 12 hours at 25°C.
Hvis du har glemt en dosis 
If you miss a dose of Xerava
Kontakt lægen eller sundhedspersonalet med det samme, hvis du tror, at en dosis måske er glemt. 
Tell your doctor or nurse immediately if you are concerned that you may have missed a dose.
Klasseeffekter for antibiotika omfatter pseudomembranøs kolitis og kraftig vækst af ikke-følsomme organismer, herunder svampe (se pkt. 
Antibiotic class adverse reactions include pseudomembranous colitis, and overgrowth of nonsusceptible organisms, including fungi (see section 4.4).
Dyrestudier har vist, at eravacyclin og dets metabolitter udskilles i human mælk (se pkt. 
Animal studies have shown excretion of eravacycline and its metabolites in breast milk (see section 5.3).
Det anbefalede dosisregime er 1 mg/kg eravacyclin hver 12. time i 4-14 dage. 
The recommended dose regimen is 1 mg/kg eravacycline every 12 hours for 4 to 14 days.
• Streptococcus spp. 
• Viridans Streptococcus spp.
Eravacyclin havde indvirkning på parringen og fertiliteten hos hanrotter ved klinisk relevante eksponeringer (se pkt. 
Eravacycline did affect mating and fertility in male rats at clinically relevant exposures (see section 5.3).
Eravacyclin-dosis 
Eravacycline dosing
MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE YDRE KARTON: 1 HÆTTEGLAS 
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON: 1 VIAL
Fortæl det til din læge eller sundhedspersonalet, hvis du har diarré, før du får Xerava. 
Talk to your doctor or nurse if you are suffering from diarrhoea before being given Xerava.
I kliniske studier af komplicerede intraabdominale infektioner var der ingen immunkompromitterede patienter, og størstedelen af dem (80 %) havde APACHE II-scorer <10 ved baseline. 
In clinical trials in cIAI, there were no immunocompromised patients, and the majority of patients (80%) had APACHE II scores <10 at baseline; 5.4% of the patients had concurrent bacteraemia at baseline; 34% of the patients had complicated appendicitis.
Antal hætteglas til rekonstitution 
Number of vials to reconstitute
Der er rapporteret om pankreatitis ved anvendelse af eravacyclin og andre antibiotika i tetracyclinklassen, i nogle tilfælde af svær grad (se pkt. 
Pancreatitis has been reported with eravacycline and other tetracycline class antibiotics, and has been severe in some cases (see section 4.8).
Xerava er indiceret til behandling af komplicerede intraabdominale infektioner hos voksne (se pkt. 
Xerava is indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults (see sections 4.4 and 5.1).
Det er således ikke nødvendigt at justere dosis, når eravacyclin administreres samtidig med CYP3A-hæmmere. 
The increased exposure is not likely to be clinically significant; thus, no dose adjustment is required when eravacycline is co-administered with CYP3A inhibitors.
Det geometriske mindste kvadraters Cmax-gennemsnit for eravacyclin steg med 8,8 % hos patienter med terminal nyresygdom vs. raske forsøgspersoner ved 90 %KI -19,4;45,2). 
The geometric least square mean Cmax for eravacycline was increased by 8.8% for subjects with end stage renal disease (ESRD) versus healthy subjects with 90% CI -19.4, 45.2.
Opløsningen bør ikke anvendes, hvis der er synlige partikler i den, eller hvis den er grumset. 
The solution should not be used if particles are present or the solution is cloudy.
Svimmelhed kan forekomme efter administration af eravacyclin (se pkt. 
Dizziness may occur following administration of eravacycline (see section 4.8).
Den anbefalede Xerava-dosis er 1 mg/kg hver 12. time i 4-14 dage. 
The recommended dose regimen of Xerava is 1 mg/kg every 12 hours for 4 to 14 days.
Der er påvist kemisk og fysisk brugsstabilitet efter rekonstitution i hætteglasset i 1 time ved temperaturer på 25 °C. 
Chemical and physical in-use stability after reconstitution in the vial has been demonstrated for 1 hour at 25°C.
I kliniske studier er der påvist effekt mod de patogener, der er anført for komplicerede intraabdominale infektioner, hvor der sås følsomhed for eravacyclin in vitro: 
Efficacy has been demonstrated in clinical studies against the pathogens listed for cIAI that were susceptible to eravacycline in vitro:
Eravacyclin-dosis bør øges med ca. 50 % (1,5 mg/kg intravenøst hver 12. time) ved samtidig administration af rifampicin eller andre potente CYP3A-inducere som f.eks. phenobarbital, karbamazepin, phenytoin eller prikbladet perikon (se pkt. 
The eravacycline dose should be increased by approximately 50% (1.5 mg/kg IV q12h) when co-administered with rifampicin or other strong CYP3A inducers such as phenobarbital, carbamazepine, phenytoin and St. John's Wort (see sections 4.2 and 4.4).
• vejrtrækningsbesvær 
• Breathing difficulties
Sådan vil du få Xerava 
How you will be given Xerava
Kontakt lægen eller sundhedspersonalet med det samme, hvis du tror, at du måske har fået for meget Xerava. 
Tell your doctor or nurse immediately if you are concerned that you may have been given too much Xerava.
Saltsyre (til justering af pH) 
Sodium hydroxide (for pH adjustment) Hydrochloric acid (for pH adjustment)
Reaktioner på infusionsstedetc a. Tromboflebitis omfatter de foretrukne termer tromboflebitis og trombose ved infusionsstedet b. Flebitis omfatter de foretrukne termer flebitis, flebitis ved infusionsstedet, overfladisk flebitis og flebitis ved injektionsstedet c. Reaktioner på infusionsstedet omfatter de foretrukne termer erytem ved injektionsstedet, hypoæstesi ved infusionsstedet, erytem ved indstiksstedet og smerter ved indstiksstedet Beskrivelse af udvalgte bivirkninger 
General disorders and administration site conditions Infusion site reactionsc a. Thrombophlebitis includes the preferred terms thrombophlebitis and infusion site thrombosis b. Phlebitis includes the preferred terms phlebitis, infusion site phlebitis, superficial phlebitis and injection site phlebitis c. Infusion site reactions includes the preferred terms injection site erythema, infusion site hypoaesthesia,
Xerava er et bleggul til mørkegul kompakt pulver i et 10 ml-hætteglas. 
Xerava is a pale yellow to dark yellow cake in a 10mL glass vial.
Virkning og anvendelse Hvad er Xerava? 
What Xerava is and what it is used for What Xerava is